Article Text

PDF
Letter response
Response to: ‘Five Factor Score in patients with eosinophilic granulomatosis with polyangiitis (Churg–Strauss; EGPA): to use or not to use?’ by Moiseev and Novikov
  1. Maxime Samson1,2,
  2. Loïc Guillevin1
  1. 1Service de Médecine Interne, Centre de Référence des Maladies Auto-immunes et de la Sclérodermie Systémique, Paris, France
  2. 2Service de Médecine Interne et Immunologie Clinique, Centre Hospitalier Universitaire de Dijon, Dijon, France
  1. Correspondence to Professor Loïc Guillevin, Service de Médecine Interne, Hôpital Cochin, 27, rue du faubourg Saint-Jacques, Paris 75679, Cedex 14, France; loic.guillevin{at}cch.aphp.fr

Statistics from Altmetric.com

Moiseev and Novikov's comments on the five-factor score (FFS) for eosinophilic granulomatosis with polyangiitis (EGPA) provide the opportunity to address the contribution of scores and their use.1 The FFS was designed to evaluate necrotising vasculitis prognosis and identify manifestations associated with death: those are its only roles. Its strength is its validation on 1108 patients with different vasculitides, including 230 with EGPA, that is, sufficient to validate its use.2 ,3 Saying that only cardiac involvement in FFS applies to EGPA is erroneous. Although a concomitant atherosclerotic process cannot be excluded, each patient's cardiac symptoms were reviewed to confirm that they were EGPA related and not attributable …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles